

Lallemand Health and Kirin Holdings announce distribution agreement for IMMUSE

16 May 2025 | News

IMMUSE has been extensively studied, with 15 clinical studies demonstrating its efficacy in supporting immune health



IMMUSE has been extensively studied, with 15 clinical studies demonstrating its efficacy in supporting immune health

Lallemand Health Solutions and Kirin Holdings Company, Limited announced their strategic partnership aimed at enhancing the visibility and market reach of IMMUSE, one of the most documented postbiotics for immune support. This collaboration leverages the distinct strengths of both companies to bring advanced immune health solutions to consumers worldwide.

IMMUSE, developed by Kirin Holdings Company, Limited, is an award-winning postbiotic, with its immune function supported by patent-protected research. It is a clinically researched lactic acid bacteria that supports immune health through a unique mode of action. This heat-inactivated *Lactococcus lactis* strain Plasma directly activates key immune cells called plasmacytoid dendritic cells, offering comprehensive immune support by stimulating both innate and adaptive immune responses.

IMMUSE has been extensively studied, with 15 clinical studies demonstrating its efficacy in supporting immune health. Key findings in the area include: a significant decrease in cough days and sore throat severity compared to placebo [Shibata, 2016], a reduction in cold-like symptoms and cumulative incidence days [Suzuki, 2015], enhanced immune response, including up-regulation of antiviral gene expression levels and increased secreted IgA levels in saliva [Fujii, 2017], promotion of exercise performance by supporting the immune system in healthy athletes [Komano, 2018 & 2023]. IMMUSE is available in a variety of dosage forms, making it easy to integrate into a daily routine.